190 related articles for article (PubMed ID: 37522128)
21. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
[TBL] [Abstract][Full Text] [Related]
22. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
23. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.
Rai A; Yelamanchi SD; Radotra BD; Gupta SK; Mukherjee KK; Tripathi M; Chhabra R; Ahuja CK; Kumar N; Pandey A; Korbonits M; Dutta P; Gaston-Massuet C
Acta Neuropathol Commun; 2022 Sep; 10(1):138. PubMed ID: 36114575
[TBL] [Abstract][Full Text] [Related]
25. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
[TBL] [Abstract][Full Text] [Related]
26. Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.
Øystese KAB; Casar-Borota O; Berg-Johnsen J; Berg JP; Bollerslev J
Endocrine; 2022 Jun; 77(1):151-159. PubMed ID: 35674926
[TBL] [Abstract][Full Text] [Related]
27. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
Mangili F; Giardino E; Treppiedi D; Barbieri AM; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Mantovani G; Peverelli E
Neuroendocrinology; 2021; 111(6):568-579. PubMed ID: 32512568
[TBL] [Abstract][Full Text] [Related]
28. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
[TBL] [Abstract][Full Text] [Related]
29. The role of the tumour microenvironment in the angiogenesis of pituitary tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Dorward N; Grieve J; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
Endocrine; 2020 Dec; 70(3):593-606. PubMed ID: 32946040
[TBL] [Abstract][Full Text] [Related]
30. Screening and identification of potential hub genes and immune cell infiltration in the synovial tissue of rheumatoid arthritis by bioinformatic approach.
Feng ZW; Tang YC; Sheng XY; Wang SH; Wang YB; Liu ZC; Liu JM; Geng B; Xia YY
Heliyon; 2023 Jan; 9(1):e12799. PubMed ID: 36699262
[TBL] [Abstract][Full Text] [Related]
31. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Proteomic-Based Molecular Characterizations of Invasive and Noninvasive Somatotroph PitNETs.
Chen M; Duan L; Sun W; Guo Z; Miao H; Yu N; Yang S; Wang L; Gong F; Yao Y; Zhu H
Neuroendocrinology; 2023; 113(9):971-986. PubMed ID: 37253344
[TBL] [Abstract][Full Text] [Related]
33. Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.
Serioli S; Agostini L; Pietrantoni A; Valeri F; Costanza F; Chiloiro S; Buffoli B; Piazza A; Poliani PL; Peris-Celda M; Iavarone F; Gaudino S; Gessi M; Schinzari G; Mattogno PP; Giampietro A; De Marinis L; Pontecorvi A; Fontanella MM; Lauretti L; Rindi G; Olivi A; Bianchi A; Doglietto F
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958702
[TBL] [Abstract][Full Text] [Related]
34. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
Kara M; Tokat F; Pamir MN; Danyeli AE
Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
[TBL] [Abstract][Full Text] [Related]
35. Erythropoietin-producing hepatocellular receptor B6 is highly expressed in non-functioning pituitary neuroendocrine tumors and its expression correlates with tumor size.
Rubinfeld H; Cohen ZR; Bendavid U; Fichman-Horn S; Levy-Barda A; David C; Melamed P; Shimon I
Mol Biol Rep; 2024 Feb; 51(1):297. PubMed ID: 38341842
[TBL] [Abstract][Full Text] [Related]
36. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
[TBL] [Abstract][Full Text] [Related]
37. Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.
Aydin B; Beklen H; Arga KY; Bayrakli F; Turanli B
J Endocrinol Invest; 2023 Apr; 46(4):727-747. PubMed ID: 36306107
[TBL] [Abstract][Full Text] [Related]
38. The Immune Microenvironment Landscape of Pituitary NeuroEndocrine Tumors, a Transcriptomic Approach.
Vela-Patiño S; Salazar MI; Taniguchi-Ponciano K; Vadillo E; Gomez-Apo E; Escobar-España A; Perez-Koldenkova V; Bonifaz L; Aguilar-Flores C; Marrero-Rodríguez D; Mercado M
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790160
[TBL] [Abstract][Full Text] [Related]
39. Six potential biomarkers in septic shock: a deep bioinformatics and prospective observational study.
Kong C; Zhu Y; Xie X; Wu J; Qian M
Front Immunol; 2023; 14():1184700. PubMed ID: 37359526
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of HOXD3 and UNC5C as molecular signatures in keloid based on weighted gene co-expression network analysis.
Wang H; Zhou Z; Liu Y; Wang P; Chen L; Qi S; Xie J; Tang J
Genomics; 2022 Jul; 114(4):110403. PubMed ID: 35709926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
